Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ — Biohaven Ltd. (NYSE: BHVN) (“Biohaven”), a global clinical-stage biopharmaceutical company focused…